Format

Send to

Choose Destination
Alzheimers Dement. 2016 Jan;12(1):60-4. doi: 10.1016/j.jalz.2015.12.003. Epub 2015 Dec 19.

Why has therapy development for dementia failed in the last two decades?

Author information

1
Alzheimer's Disease Research Unit/Memory Clinic, McGill Centre for Studies in Aging, Montreal, Quebec, Canada.
2
Division of Cognitive Neuroscience, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
3
Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
4
Division of Neurobiology, MRC Laboratory of Molecular Biology, Cambridge, UK.
5
Center for Alzheimer Research and Aging Research Center (ARC), Karolinska Institutet, Department of Geriatric Medicine Clinical Trials Unit, Karolinska University Hospital, Huddinge, Sweden.
6
Office of Health Economics, London, UK.
7
Neuroepidemiology and Ageing Research, School of Public Health, Imperial College London, London, UK. Electronic address: l.middleton@imperial.ac.uk.

Abstract

The success rate of the pharmaceutical research and development (R&D) for dementia drugs has been abysmally low, in the last two decades. Also low has been the number of pipeline drugs in development, compared to other therapy areas. However, the rationale of early terminations has not been reported in the majority of trials. These are key findings of the recently published pharmaceutical pipeline analysis by the UK-based Office of Health Economics (OHE). Our understanding of main challenges include (1) the significant gaps of knowledge in the nosology and complexity of the underpinning biological mechanisms of the commonest, not familial, forms of late onset dementias; (2) low signal-to-noise ratio, notwithstanding the lack of validated biomarkers as entry and/or end-point criteria; (3) recruitment and retention, particularly in the asymptomatic and early disease stages. A number of current and future strategies aimed at ameliorating drug development are outlined and discussed.

KEYWORDS:

Alzheimer's; Amyloid hypothesis; Attrition; Clinical trials; Dementia; Research & development

PMID:
26710325
DOI:
10.1016/j.jalz.2015.12.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center